Table 3.
Baseline laboratory findings of female and male patients infected with SARS-CoV-2
| All patients (n = 317) | Females (n = 155) | Males (n = 162) | P value | |
|---|---|---|---|---|
| White blood cell count, × 10^9/L | 5.6 (4.4–7.8) | 5.2 (4.1–7.5) | 5.8 (4.8–8.0) | 0.045 |
| Neutrophil count, × 10^9/L | 4.0 (2.9–6.3) | 3.6 (2.6–5.9) | 4.3 (3.1–6.4) | 0.024 |
| Lymphocyte count, × 10^9/L | 0.9 (0.6–1.3) | 1.0 (0.7–1.3) | 0.8 (0.6–1.1) | 0.45 |
| Hemoglobin, g/L | 127.0 (116.0–139.0) | 120.0 (112.0–128.0) | 136.0 (125.8–144.0) | < 0.001 |
| Platelet count, ×10^9/L | 208.0 (154.0–285.0) | 233.0 (164.0–307.0) | 190.0 (141.8–254.0) | < 0.001 |
| Albumin, g/L | 33.7 (30.8–36.8) | 34.0 (31.3–37.8) | 33.4 (30.2–36.1) | 0.037 |
| Blood bicarbonate ions, mmol/L | 23.5 (21.7–25.1) | 23.8 (21.8–25.5) | 23.3 (21.6–24.8) | 0.231 |
| Blood urea nitrogen, mmol/L | 4.6 (3.5–6.0) | 4.2 (3.2–5.3) | 4.9 (3.8–6.5) | < 0.001 |
| Blood creatinine, μmol/L | 70.0 (57.5–86.0) | 58.0 (52.0–70.0) | 81.0 (68.0–95.0) | < 0.001 |
| Lactate dehydrogenase, U/L | 302.0 (237.0–425.0) | 272.0 (223.0–345.0) | 324.0 (254.0–471.5) | < 0.001 |
| High-sensitivity C-reactive protein, mg/L | 41.1 (11.8–90.6) | 23.4 (7.1–69.3) | 66.0 (25.9–121.4) | < 0.001 |
| Procalcitonin, ng/mL | 0.06 (0.03–0.17) | 0.04 (0.02–0.09) | 0.09 (0.05–0.23) | < 0.001 |
| Ferritin, μg/L | 751.5 (435.7–1333.9) | 533.2 (264.8–932.6) | 1069.85 (611.4–1734.2) | < 0.001 |
| Soluble interlukin-2 receptor, U/mL | 762.0 (509.9–1124.0) | 678.0 (501.0–1023.0) | 879.0 (625.8–1232.0) | 0.001 |
| Interleukin-6, pg/mL | 21.7 (7.3–53.9) | 15.2 (3.9–40.0) | 33.0 (12.0–68.5) | < 0.001 |
| Interleukin-8, pg/mL | 15.5 (9.4–26.6) | 15.1 (9.2–26.0) | 16.0 (9.6–28.2) | 0.261 |
| Interleukin-10, pg/mL | 5.6 (5.00–9.4) | 5.0 (5.0–8.5) | 6.6 (5.0–10.2) | 0.12 |
| Tumor necrosis factor alpha, pg/mL | 9.1 (7.2–12.1) | 8.7 (6.8–11.6) | 9.7 (7.6–13.0) | 0.093 |
Data are expressed as median (IQR) or n (%)